BLA 761440 · Glaxosmithkline LLC
Blenrep
Belantamab Mafodotin-Blmf · Injection
OrphanLast checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
72
10 Phase 3, 16 recruiting
FAERS reports
3,107
2,738 serious, 1,042 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: OCULAR TOXICITY • BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred [see Warnings and Precautions ( 5.1 )] . • Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 )] . • Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS) [see Warnings and...
What it is approved for
From the label in effect Oct 23, 2025.
BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP, a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate, is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. ( 1 )
Mechanism: Belantamab mafodotin‑blmf is an antibody‑drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is mcMMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin‑blmf is internalized followed by release of the cytotoxic agent (cys‑mcMMAF) via proteolytic cleavage. The released cys‑mcMMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis. Belantamab mafodotin‑blmf had antitumor activity in multiple...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BLENREP · BELANTAMAB MAFODOTIN-BLMF 70MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Belantamab Mafodotin" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT06679101 · 520 participants (planned) · Start Dec 16, 2024 · Primary completion Apr 28, 2031
Drug: Belantamab mafodotin; Lenalidomide and 2 more · For: Multiple Myeloma; Newly Diagnosed Multiple Myeloma
Sites: Mobile, Alabama; Phoenix, Arizona; Beverly Hills, California · 181 sites in all
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
PrECOG, LLC.Academic, hospital or other
NCT07285239 · 500 participants (planned) · Start Dec 2026 · Primary completion Nov 2031
Drug: Arm A: Belantamab Mafodotin; Arm B: Daratumumab Hyaluronidase and 3 more · For: Multiple Myeloma
Sites: Des Moines, Iowa; Brewer, Maine; La Crosse, Wisconsin
- Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04246047 · 494 participants · Start May 7, 2020 · Primary completion Oct 2, 2023
Drug: Belantamab mafodotin; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Yuma, Arizona; Mission, Kansas; Denver, North Carolina · 143 sites in all
- Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04162210 · 325 participants · Start Apr 2, 2020 · Primary completion Sep 12, 2022
Drug: Belantamab mafodotin; Pom/dex (Pomalidomide plus low dose Dexamethasone) · For: Multiple Myeloma
Sites: Tucson, Arizona; Pueblo, Colorado; Detroit, Michigan · 136 sites in all
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04484623 · 302 participants · Start Oct 1, 2020 · Primary completion Jan 29, 2024
Drug: Belantamab mafodotin; Pomalidomide and 2 more · For: Multiple Myeloma
Sites: Tucson, Arizona; Fort Myers, Florida; Boston, Massachusetts · 122 sites in all
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsPivotal-lookingRecruiting
Karyopharm Therapeutics IncIndustry
NCT02343042 · 300 participants (planned) · Start Oct 2015 · Primary completion Apr 2027
Drug: Selinexor; Dexamethasone and 10 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Los Angeles, California; Denver, Colorado · 25 sites in all
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Pivotal-lookingNot yet recruiting
Polish Myeloma ConsortiumAcademic, hospital or other
NCT07748689 · 228 participants (planned) · Start Oct 2026 · Primary completion Mar 2033
Drug: Belantamab Mafodotin; Pomalidomide and 1 more · For: Relapsed / Refractory Multiple Myeloma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- keratopathy856
- visual acuity reduced800
- death586
- plasma cell myeloma455
- dry eye404
- night blindness317
- vision blurred204
- photophobia189
- foreign body sensation in eyes186
- ocular toxicity168
- visual impairment131
- punctate keratitis130
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 185 |
| 2021 | 776 |
| 2022 | 1,149 |
| 2023 | 270 |
| 2024 | 82 |
| 2025 | 160 |
| 2026 | 482 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Hungria V, Robak P, Hus M, et al. · Lancet Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Trudel S, McCurdy A, Louzada ML, et al. · Nat Med 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis.
Richter J, Nooka A, Rodríguez-Otero P, et al. · Am J Hematol 2025 · Systematic Review, Comparative Study
- Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
Terpos E, Trudel S, Mateos MV, et al. · Am J Hematol 2025 · Systematic Review, Practice Guideline
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.